Screener / SEC EDGAR /CIK 0001723128 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Amneal Pharmaceuticals, Inc. AMRX

Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. 10-K, Item 1

Employees
8,500
Next results
around Jan 12, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $3.0B through the costs to a net profit of $72.1M · income statement of the 10-K

13% operating margin
Revenue to Gross profit: $1.1BRevenue to Cost of revenue: $1.9BGross profit to Operating profit: $394.1MGross profit to Operating expenses: $719.2MOperating profit to Net profit: $72.1MOperating profit to Tax & other: $322.0MOperating expenses to R&D: $186.2MOperating expenses to SG&A: $533.0M Revenue: $3.0B REVENUE $3.0B +8% Y/Y Gross profit: $1.1B · 37% margin GROSS PROFIT $1.1B 37% margin · +9% Y/Y Cost of revenue: $1.9B · 63% of revenue COST OF REVENUE $1.9B 63% of revenue Operating profit: $394.1M · 13% margin OPERATING PROFIT $394.1M 13% margin · +58% Y/Y Operating expenses: $719.2M · 24% of revenue OPERATING EXPENSES $719.2M 24% of revenue Net profit: $72.1M · 2% margin NET PROFIT $72.1M 2% margin Tax & other: $322.0M · 11% of revenue TAX & OTHER $322.0M 11% of revenue R&D: $186.2M · 6% of revenue R&D $186.2M 6% of revenue SG&A: $533.0M · 18% of revenue SG&A $533.0M 18% of revenue
Gross profit $1.1B 37% margin · +9% Y/Y
Operating profit $394.1M 13% margin · +58% Y/Y
Net profit $72.1M 2% margin
The full income statement, year by year

AMRX among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 8.0%, above 40% of 154 peers (their median 10.5%) REVENUE GROWTH 8.0% · above 40% Gross margin: 40.2%, above 21% of 107 peers (their median 63.8%) GROSS MARGIN 40.2% · above 21% Operating margin: 15.0%, above 69% of 138 peers (their median 9.8%) OPERATING MARGIN 15.0% · above 69% Net margin: 4.2%, above 46% of 153 peers (their median 6.8%) NET MARGIN 4.2% · above 46% FCF margin: 2.8%, above 26% of 144 peers (their median 10.1%) FCF MARGIN 2.8% · above 26% Return on capital: 10.4%, above 61% of 89 peers (their median 9.0%) RETURN ON CAPITAL 10.4% · above 61%
AMRX Peer median Below the median

What changed

11 new risk paragraphs. 10-K filed Feb 27, 2026 against Feb 28, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

10 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 10 checks found nothing to note

  • Cash from operations $340.0M vs net income $72.1M (FY ending Dec 31, 2025)
  • Inventory -1.0% ($612.5M to $606.3M) vs revenue +8.0% ($2.8B to $3.0B), -9.1 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
7 more checks with nothing to note
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Medicaid Rebates; Sales Returns
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

11 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.

All 11 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    We are subject to certain trade and tariff requirements imposed by the U.S. and various foreign governments. The great majority of our net sales rely on finished dosage forms (“FDF”) or API produced in the U.S. or India. We have limited reliance on imports from Europe and China, and no reliance on imports from Mexico or Canada. Since…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    We rely on information technology systems for critical functions, including supply chain management, transaction processing, finance, human resources, sales order management, compliance, and reporting. In 2025, we began a multi-year enterprise resource planning (“ERP”) system implementation for certain parts of our business to integrate…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    We rely on our internal technology systems and websites to run our business as well as our or our third-party partners’ physical facilities, such as our R&D or manufacturing premises. In addition, we rely on third-party hosted services. A disruption, infiltration or failure of these systems, facilities or third-party hosted services in…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Escalating geopolitical tensions or military conflict between India and Pakistan could disrupt our operations, supply chain, or workforce in the region, potentially resulting in production delays, increased costs, or reduced availability of key materials. Any sustained instability in the region could also impair our ability to maintain…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$2.2B$2.4B$2.8B$3.0B
Net income−$270.6M−$84.0M−$116.9M$72.1M
Operating cash flow$65.1M$345.6M$295.1M$340.0M
Free cash flow$18.7M$302.4M$243.2M$269.9M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$3.0B ▲ 8.0% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Amneal Pharmaceuticals, Inc. · from the 10-K filed Feb 27, 2026

Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States (“U.S.”), India, and Ireland.

Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 3, 2026

Employees, at the top of the page: "As of December 31, 2025, we had over 8,500 employees (“Amneal Employees”), excluding approximately 200 employees in our AvKARE segment" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AMRX/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.